Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFAMPIN AND ISONIAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFAMPIN AND ISONIAZID.
ARIKAYCE KIT vs RIFAMPIN AND ISONIAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Rifampin inhibits bacterial DNA-dependent RNA polymerase, blocking RNA synthesis. Isoniazid inhibits mycolic acid synthesis in Mycobacterium tuberculosis cell wall.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
2 tablets (rifampin 300 mg/isoniazid 150 mg) or 2 tablets (rifampin 600 mg/isoniazid 300 mg) orally once daily depending on formulation. Each dose should be taken on an empty stomach at least 30 minutes before or 2 hours after a meal.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Rifampin: 2-5 hours (terminal); decreases with repeated dosing due to autoinduction. Isoniazid: 0.5-1.5 hours (fast acetylators), 2-5 hours (slow acetylators); clinical context: dosing interval adjustment based on acetylator status.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Rifampin: primarily hepatic (biliary) excretion (60-65% as unchanged drug), with 30% renal (15% unchanged). Isoniazid: renal excretion (75-95% as metabolites, 5-27% unchanged); acetylation phenotype-dependent; 70% renal in fast acetylators, 90% in slow.
Category C
Category A/B
Antimycobacterial
Antimycobacterial